Wednesday, July 8, 2026

Patent intelligence · US

US 11707472

Compositions for the treatment of fibrosis

granted A61KA61K31/19A61K31/662A61K31/663
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 17
Applicant portfolio 15
Patent details — US 11707472
Jurisdiction
US
Status
granted
Grant date
Jul 25, 2023
Expiration
Jul 20, 2043
Claims
21
CPC classes
A61K, A61K31/19, A61K31/662, A61K31/663
View on Google Patents ↗

Quick answer

US 11707472 (Compositions for the treatment of fibrosis) is held by Viking Therapeutics, Inc.. Status: granted. Granted Jul 25, 2023. Expires Jul 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
21
CPC classes
A61K, A61K31/19, A61K31/662, A61K31/663, A61K31/664, A61K31/665

More from Viking Therapeutics, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12421282

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Expires Sep 18, 2045

    granted
  2. US 12318426

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Expires May 29, 2045

    granted
  3. US 12102646

    Compositions for the treatment of fibrosis and inflammation

    Viking Therapeutics, Inc. · Expires Sep 26, 2044

    granted
  4. US 12083184

    Hydrogel prodrug for treatment

    Viking Scientific, Inc. · Expires Sep 5, 2044

    granted
  5. US 11951114

    Use of thyroid beta-agonists

    Viking Therapeutics, Inc. · Expires Apr 4, 2044

    granted
  6. US 11752217

    Hydrogel prodrug for treatment

    Viking Scientific, Inc. · Expires Sep 7, 2043

    granted
  7. US 11744873

    Compositions and methods for the treatment of metabolic and liver disorders

    Viking Therapeutics, Inc. · Expires Aug 31, 2043

    granted

Frequently asked questions

What is US patent 11707472?

US 11707472 (Compositions for the treatment of fibrosis) is held by Viking Therapeutics, Inc.. Status: granted. Granted Jul 25, 2023. Expires Jul 20, 2043 (17 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 11707472?

Viking Therapeutics, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 15 pharmaceutical patents for this assignee.

When does US 11707472 expire?

Our index shows an expiration date of Jul 20, 2043 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.